TOXINA BOTULÍNICA PARA TRATAR DOR NEUROPÁTICA PERIFÉRICA

A specific botulinum toxin injection regimen effectively treats peripheral neuropathic pain with minimal side effects, filling a gap in current treatments by providing a safe and non-opioid solution.

BR112025025140A2Pending Publication Date: 2026-11-10MERZ THERAPEUTICS GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025025140
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2024-05-23
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current treatments for peripheral neuropathic pain are limited by chronicity, side effects, and the need for safe, non-opioid alternatives, with no established dose or regimen for botulinum toxin administration.

Method used

A specific dosage and injection regimen for botulinum toxin, administered subcutaneously at 35 U/ml to 65 U/ml, 4.0 U to 6.0 U per injection, and 0.07 ml to 0.15 ml per point, with 1.5 cm to 2.5 cm between points, effectively treats peripheral neuropathic pain.

Benefits of technology

The regimen provides significant pain relief with minimal side effects, addressing the limitations of existing treatments by offering a safe and effective, non-opioid option for neuropathic pain management.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to the use of botulinum toxin for the treatment of peripheral neuropathic pain (PNP) by local administration of botulinum toxin. The administration involves subcutaneous injection of an effective amount of botulinum toxin in the pain-affected skin area of a patient according to a specific administration regimen. The peripheral neuropathic pain can be, for example, post-herpetic neuralgia, peripheral nerve injury (e.g., due to surgery or trauma), trigeminal neuralgia, painful polyneuropathy (e.g., diabetic neuropathic pain), and painful radiculopathy.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 42 Botulinum toxin to treat peripheral neuropathic pain. Field of Invention

[001] The present invention relates to the use of botulinum toxin for the treatment of peripheral neuropathic pain (PNP) by means of local administration of botulinum toxin. Administration involves subcutaneous injection of an effective amount of botulinum toxin into the area of ​​skin of a patient affected by pain, according to a specific administration regimen. Peripheral neuropathic pain may be, for example, post-herpetic neuralgia, peripheral nerve injury (e.g., due to surgery or trauma), trigeminal neuralgia, painful polyneuropathy (e.g., diabetic neuropathic pain), and painful reticulopathy. Fundamentals of the Invention

[002] Pain is currently defined by the International Association for the Study of Pain (IASP) as an unpleasant sensory and emotional experience associated with, or resembling such association with, actual or potential tissue damage (Raja et al., Pain, 2020, 161(9):1976-1982). Among the different types of pain, neuropathic pain (NP) is characterized by increased sensitivity to pain and / or spontaneous pain and is defined by the IASP as pain caused by an injury or disease of the somatosensory nervous system” (Scholz Petition 870250104861, dated 11 / 17 / 2025, page 21 / 66 2 / 42 et al., Pain, 2019, 160(1):53-59). This type of pain can be felt far from the lesion or disease of the nervous system (Raja et al, supra). Neuropathic pain can result from etiologically varied disorders, and the underlying pathophysiological mechanisms are complex, about which there is no complete understanding (Scholz, supra). Approximately 6-10% of adults are affected by chronic pain with neuropathic characteristics (Kamerman et al., 2015, Pain, 156(5):793-797), with detrimental consequences to quality of life related to psychosocial well-being and health.

[003] Depending on the location of the lesion or disease, neuropathic pain can be classified as peripheral neuropathic pain (PNP) and central neuropathic pain (CNP). PNP is defined as pain caused by a lesion or disease of the peripheral somatosensory nervous system, while CNP is defined as pain caused by a lesion or disease of the central somatosensory nervous system. The most common PNP conditions include trigeminal neuralgia, peripheral nerve injury, painful polyneuropathy (e.g., diabetic neuropathic pain), postherpetic neuralgia, and painful radiculopathy. Central neuropathic pain conditions include pain caused by spinal cord or brain injury, post-stroke pain, and pain associated with multiple sclerosis (Scholz et al., supra). Petition 870250104861, dated 11 / 17 / 2025, p. 22 / 66 3 / 42

[004] Treatment of neuropathic pain is challenging due to the chronic course of the disease and the existing limitations of non-pharmacological and pharmacological approaches. An unmet medical need for new treatment options for neuropathic pain, specifically PNP, stems notably from the current limitations presented by first- and second-line pharmacological treatments, mostly oral. Many patients do not obtain sufficient pain relief with approved medications or do not tolerate systemic drugs due to prevalent side effects such as dry mouth, nausea, or drowsiness, which often leads to discontinuation of therapy (Finnerup et al., Lancet Neurol., 2015, 14(2):162-173). Furthermore, there is a need for safe, effective, and non-opioid drug options for pain management, as opioid misuse and addiction are a growing public health challenge (Coussens et al., J. Pharmacol. Exp. Ther., 2019, 371(2):396-408).

[005] Local injection treatment with botulinum toxin (botulinum neurotoxin or BoNT) is a new and emerging treatment option. BoNT is a potent neurotoxin produced by Clostridium botulinum, and its putative mechanism of action in neuropathic pain may involve, among other things, the inhibition of the release of neurotransmitters and pain mediators (e.g., substance P, the Petition 870250104861, dated 11 / 17 / 2025, page 23 / 66 4 / 42 glutamate and calcitonin gene-related protein (CGRP), and the reduction in the activity of transient receptor potential (TRP) ion channels involved in the transduction of harmful effects (Go et al., Front. Mol. Neurosci., 2021, 14:772719, doi: 10.3389 / fnmol.2021.772719; JH Park and HJ Park, Toxins, 2017, 9(9):260). In recent years, several clinical trials with BoNT for the treatment of peripheral neuropathic pain have shown promising efficacy and safety in BoNT treatment in various PNP conditions.

[006] In a randomized, double-blind, two-arm, single-dose, placebo-controlled clinical trial conducted by Apalla et al. (Clin. J. Dor., 2013, 29(10):857-64), the efficacy and safety of BoNT Type A, Botox®, were evaluated in patients with postherpetic neuralgia. Each patient received 40 injections, each with 5 U of Botox®, resulting in a maximum total dose of 200 U. The injections were administered subcutaneously in a grid pattern, with a minimum distance of 1 cm between injection sites. It was concluded that botulinum toxin type A (BoNT type A) is a promising therapeutic modality for postherpetic neuralgia. Furthermore, Attal et al. (Lancet Neurol., 2016, 15(6):555-65), in a randomized trial, Petition 870250104861, dated 11 / 17 / 2025, page 24 / 66 A 5 / 42 double-blind, two-arm, placebo-controlled trial investigated the efficacy and safety of BoNT Type A, Botox®, in patients with peripheral neuropathic pain (conditions other than PNP were included). The total dose of BoNT Type A, Botox®, was determined by the size of the painful area, not exceeding 60 injection sites (i.e., not exceeding a total dose of 300 U). Injections were administered subcutaneously, 0.2 ml (5 U) per injection site, with injection sites spaced 1.5 to 2 cm apart. In conclusion, two administrations of BoNT Type A had a prolonged analgesic effect against peripheral neuropathic pain.

[007] Other PNP trials using botulinum toxin include the randomized, double-blind, placebo-controlled single-dose study by Ghasemi et al. (J. Res. Med. Sci., 2014, 19(2):106-111), in which 40 participants with diabetic PNP in both feet received intradermal injection of BoNT Type A (Dysport®) at 12 injection points in a grid (3x4 injection points) on the dorsum of one foot. The authors concluded that BoNT Type A has a significant effect on diabetic peripheral neuropathic pain. Ranoux et al. (Ann. Neurol., 2008, 64(3):274-283) reported a double-blind, placebo-controlled, parallel-group clinical trial design study in which the use of BoNT Type A was investigated, Petition 870250104861, dated 11 / 17 / 2025, p. 25 / 66 6 / 42 Botox® was studied in 29 patients with focal painful neuropathies (e.g., post-traumatic / post-operative pain or post-herpetic neuralgia) associated with mechanical allodynia. Botox® or placebo was injected intradermally into the skin, spaced 1.5 cm apart, without exceeding the predetermined maximum number of sites, which was set at 40 (corresponding to a maximum dose of 200 units). The authors concluded that transdermal injection of BoNT Type A has direct analgesic effects in patients with chronic focal neuropathic pain associated with allodynia.

[008] Furthermore, in the randomized, double-blind, placebo-controlled single-dose study by Taheri et al. (Diabetes Metab. Syndr., 2020,14(6):1823-1828), it was found that transdermal injection of BoNT in patients with painful diabetic neuropathy, using injections in a 4x5 grid with a 1 cm distance between them, is effective in reducing neuropathic pain and improving symptoms associated with neuropathic pain. Xiao et al. (Pain Med., 2010, 11(12):1827-1833), in a prospective, randomized, placebo-controlled, double-blind clinical trial conducted in China, demonstrated that subcutaneous injection of BoNT Type A (Lanzhou Institute of Biological Products, China) into the affected area of ​​individuals with postherpetic neuralgia within a skin radius of 1.0 to 2.0 cm using a volume of 1 ml (total dose of 77 ± 18.5 U of BoNT Type A) decreased Petition 870250104861, dated 11 / 17 / 2025, page 26 / 66 7 / 42 significantly reduced pain in postherpetic neuralgia. Yuan et al. (Neurology, 2009, 72(17):1473-1478) conducted a double-blind, placebo-controlled crossover trial in 18 patients to evaluate the efficacy of intradermal BoNT Type A (Botox®) for diabetic neuropathic pain. In this trial, BoNT Type A, Botox®, was administered intravenously into each patient's foot in a grid pattern (typically spaced 2–3 cm apart covering a total of 12 sites), with each injection comprising approximately 4 U of Botox® in a volume of 0.1 ml. The authors found that BoNT Type A significantly reduced diabetic neuropathic pain and transiently improved sleep quality.

[009] In addition, four randomized, double-blind, placebo-controlled, single-dose studies investigated the effect of BoNT Type A, Botox® (Shehata et al., J. Headache Pain, 2013, 14(1):92, Zuniga et al., Clin. de Neuropharmacol., 2013, 36(5):146-150) and BoNT Type A (Lanzhou Institute of Biological Products, China) (Wu et al., Cephalagia, 2012, 32(6):443-450; Zhang et al., J. Headache Pain, 2014, 15(1):65) on trigeminal neuralgia. All studies demonstrated statistically significant superiority of BoNT / A compared to placebo in reducing pain and, where reported, also in the frequency of pain attacks. However, in contrast to these positive clinical trial results, in a multicenter trial, Petition 870250104861, dated 11 / 17 / 2025, page 27 / 66 In a double-blind, placebo-controlled, parallel-group trial sponsored by Allergan, registered as NCT00168441 on the ClinicalTrials.gov website, no statistically significant difference was found between treatment with BoNT Type A (Botox®) involving 2 to 80 intradermal injections (5 U to 200 U) and placebo in patients with postherpetic neuralgia.

[0010] Although the results of various clinical studies reflect the advantages of non-systemic minimally invasive BoNT therapy, compared to established approaches for neuropathic pain relief, there is no established dose, maximum dose, dilution, number of injection sites, or distance between injection sites for BoNT product in the treatment of neuropathic pain. Object of the Invention

[0011] In view of the content described, the object of the present invention is how to provide an improved treatment for peripheral neuropathic pain. Summary of the Invention

[0012] The present invention relates to the use of botulinum toxin for the treatment of peripheral neuropathic pain. It has been found that the use of a specific dosage and injection regimen for the administration of botulinum toxin is highly effective in reducing peripheral neuropathic pain while being tolerable and safe. Petition 870250104861, dated 11 / 17 / 2025, p. 28 / 66 9 / 42

[0013] In a first aspect, the present invention relates to a botulinum toxin for use in the treatment of peripheral neuropathic pain, wherein the botulinum toxin is injected subcutaneously into an area of ​​a patient's skin at a concentration of 35 U / ml to 65 U / ml and at a dose of 4.0 U to 6.0 U per injection point and a volume of 0.07 ml to 0.15 ml per injection point, and wherein the distance between injection points is 1.5 cm to 2.5 cm.

[0014] Peripheral neuropathic pain is preferably selected from the group consisting of post-herpetic neuralgia (PHN), peripheral nerve injury (e.g., due to surgery or trauma), trigeminal neuralgia, painful polyneuropathy (e.g., diabetic neuropathic pain (DNP)), and painful reticulopathy. In the context of the present invention, PNP is post-herpetic neuralgia in a particular preferred manner (PHN), PNP due to peripheral nerve injury, in particular, peripheral nerve injury due to surgery or peripheral nerve injury due to trauma, or painful polyneuropathy, in particular, diabetic neuropathic pain (DNP).

[0015] In the context of the present invention, botulinum toxin is preferably of type A. Furthermore, the botulinum toxin may be in a form that is free of Petition 870250104861, dated 11 / 17 / 2025, p. 29 / 66 10 / 42 complexing proteins or is in the form of a complex containing complexing proteins. Preferably, botulinum toxin is type A and is in a form that is free of complexing proteins or, in an alternative preferred embodiment, is type A and is in the form of a complex containing complexing proteins.

[0016] In a second aspect, the present invention relates to a method for the treatment of peripheral neuropathic pain, wherein the method comprises administering an effective amount of botulinum toxin by subcutaneous injection into an area of ​​a patient's skin at a concentration of 35 U / ml to 65 U / ml, and at a dose of 4.0 U to 6.0 U per injection point and a volume of 0.07 ml to 0.15 ml per injection point, and wherein the distance between injection points is 1.5 cm to 2.5 cm.

[0017] The preferred embodiments are presented in the attached dependent claims and in the detailed description below. Detailed Description of the Invention

[0018] The present invention provides a specific dosage and injection regimen that results in beneficial effects in the treatment of peripheral neuropathic pain with BoNT injections. The BoNT dosage and injection regimen is not only highly efficient in reducing PNP and associated symptoms, but is also well tolerated. Petition 870250104861, dated 11 / 17 / 2025, page 30 / 66 11 / 42 and safe. BoNT is injected locally into painful areas of the skin. It is a minimally invasive treatment modality that presents minimal side effects. Compared to commonly prescribed systemic drugs, local injection treatment with BoNT does not present prevalent side effects (e.g., dry mouth, nausea, and drowsiness) and does not involve the problem of opioid misuse and addiction. Thus, in terms of efficacy, safety, and tolerability, specific local injection treatment with BoNT according to the present invention is a favorable therapeutic approach for the treatment of peripheral neuropathic pain.

[0019] The advantages mentioned are the result of a specific combination of different administration aspects, including route of administration (subcutaneous injections), distance between injection sites (preferably 2 cm), dose of BoNT per injection site (preferably 5 U), concentration (preferably 50 U of BoNT per 1 ml), total number of injection sites (maximum 90), and total dose (maximum 400 U). This unique local treatment regimen makes a significant contribution to the technique by establishing a new treatment option in the management of neuropathic pain. Local treatment fills an important gap in this painful chronic condition, with a medical need for an effective therapeutic option. Petition 870250104861, dated 11 / 17 / 2025, p. 31 / 66 12 / 42 without systemic side effects, in an area of ​​opioid overuse, misuse, and addiction.

[0020] As defined in this document, the term peripheral neuropathic pain or PNP refers to pain caused by an injury or disease of the peripheral somatosensory nervous system. This does not include central neuropathic pain (CNP), which is defined as pain caused by an injury or disease of the central somatosensory nervous system. Causes of peripheral neuropathic pain include, for example, postherpetic neuralgia, peripheral nerve injury (e.g., due to surgery or trauma), trigeminal neuralgia, painful polyneuropathy (e.g., diabetic neuropathic pain (DNP)), and painful reticulopathy. In the context of the present invention, PNP is, or preferably is, caused by postherpetic neuralgia (PHN), PNP due to peripheral nerve injury (e.g., due to surgery or trauma), or painful polyneuropathy, in particular, diabetic neuropathic pain (DNP).

[0021] The type of pain is not limited to this and includes all symptoms of PNP. For example, some patients have allodynia, which is a symptom of PNP. Patients with allodynia feel pain from a stimulus that should not cause pain (for example, a patient who puts on a shirt and feels pain when the fabric touches their skin, or a patient who feels pain when washing their hands with warm water). However, allodynia Petition 870250104861, dated 11 / 17 / 2025, page 32 / 66 13 / 42 is just one of several symptoms of PNP. Other symptoms include, for example, tingling, numbness, electric shocks, etc. There are some hypotheses that allodynia may be a symptom quite susceptible to treatment with botulinum toxin and, therefore, any treatment of a patient suffering from PNP and allodynia should be understood as including the treatment of allodynia.

[0022] The term "patient's skin area," as used in this document, generally refers to the area of ​​skin affected by PNP, also referred to in this document as the PNP area, PNP skin area, painful area, painful skin area, or area of ​​skin affected by pain. The location and size of the painful area to be obtained are highly individual and patient-dependent. In particular, the location and size of the painful area depend on the nerves that were damaged and the cause of the PNP. However, for postherpetic neuralgia, although it can occur anywhere on the body, PNP often occurs on the chest. Furthermore, the areas associated with postherpetic neuralgia may be larger than the larger areas with nerve damage. Diabetic PNP typically occurs first on both feet, but can also appear on the hands and, as it progresses, affects the legs, arms, and other parts of the body. Post-surgical / post-traumatic PNP occurs whenever nerve damage occurs.Regarding the assessment of the area with PNP, that's correct. Petition 870250104861, dated 11 / 17 / 2025, page 33 / 66 14 / 42 is usually done by the doctor responsible for the treatment, who asks the patient to indicate the painful area. Usually, patients are able to accurately mark the painful area.

[0023] The term patient, as used in this document, is not limited to this and generally refers to a human being who needs treatment for pain. Preferably, a patient in the context of the present invention is a human being who has PNP classified as least possible by the NeuPSIG / IASP classification system (Finnerup et al., Neuropathic pain: an updated grading system for research and clinical practice Pain, 2016, 157(8):1599-1606).

[0024] In this document, numerical values ​​without decimal places should be understood as including all numerical values ​​with one or more decimal places that, applying common rounding rules, generate the numerical value without decimal places. For example, the numerical value 50 includes 49.5 or 49.50 (which are rounded to 50) and 50.4 or 50.49 (which are rounded to 50), and all numerical values ​​in that range. Similarly, it should be understood that all numerical values ​​with two or more decimal places that, applying common rounding rules, generate the numerical value with one decimal place (for example, 3.95 and 4.04 are rounded up / down) are included. Petition 870250104861, dated 11 / 17 / 2025, p. 34 / 66 15 / 42 to 4.0). Furthermore, numerical values ​​with two decimal places should be understood as including all numerical values ​​with three or more decimal places that, applying common rounding rules, generate the numerical value with two decimal places (for example, 0.085 and 0.094 are rounded up / down to 0.09). Regarding the endpoints of the ranges, the same applies; for example, a range of 35 to 65 includes the range of 34.5 to 65.4, a range of 1.5 to 2.5 includes a range of 1.45 to 2.54, and a range of 0.07 to 0.15 includes the range of 0.065 to 0.154.

[0025] The term “comprising”, like the terms “including” and “containing” and any variations thereof, such as “comprising”, “includes” and “contains”, are intended to refer to a non-exclusive inclusion; so that a process, method, product as produced by the process, composition or formulation comprising, including or containing an element or list of elements may not only include the elements, but may also include other elements not expressly listed for such process, method, product as produced by the process, composition or formulation. Furthermore, in the context of the present invention, each of the terms “comprising”, “including”, “containing”, “containing”, and any variations thereof may be replaced by the term “consisting” or “consisting”, or any variation thereof. Petition 870250104861, dated 11 / 17 / 2025, p. 35 / 66 16 / 42 of the same, which will be understood as referring to an exclusive inclusion of the indicated elements. Furthermore, the terms "a," "an," "the," and similar references used in the context of the present invention should be interpreted as encompassing both the singular and the plural and, therefore, may also refer to at least one or more than one, unless otherwise indicated in this document or clearly contradicted by the context.

[0026] In a first aspect, the present invention relates to a botulinum toxin for use in the treatment of peripheral neuropathic pain, wherein the botulinum toxin is injected subcutaneously into an area of ​​a patient's skin at a concentration of 35 U / ml to 65 U / ml and at a dose of 4.0 U to 6.0 U per injection point and a volume of 0.07 ml to 0.15 ml per injection point, and wherein the distance between injection points is 1.5 cm to 2.5 cm.

[0027] According to the present invention, the injection volume per injection point is preferably 0.07 ml to 0.14 ml, more preferably 0.08 ml to 0.13 ml, even more preferably 0.08 ml to 0.12 ml, even more preferably 0.09 ml to 0.11 ml, and most preferably 0.10 ml. More specifically, the injection volume per injection point in accordance with the present invention may be within the range of 0.07 ml to 0.14 ml and is preferably 0.07 ml to 0.13 ml, more preferably Petition 870250104861, dated 11 / 17 / 2025, pp. 36 / 66 17 / 42 preferred, 0.07 ml to 0.12 ml, in an even more preferred way, 0.07 ml to 0.11 ml or, in a preferred way, 0.08 ml to 0.15 ml, in a more preferred way, 0.08 ml to 0.14 ml, in an even more preferred way, 0.08 ml to 0.13 ml, in an even more preferred way, 0.08 ml to 0.12 ml, in a particularly preferred way, 0.08 ml to 0.11 ml or, in a preferred way, 0.09 ml to 0.15 ml, in a more preferred way, 0.09 ml to 0.14 ml, in an even more preferred way, 0.09 ml to 0.13 ml, in an even more preferred way, 0.09 ml to 0.12 ml, and in a particularly preferred way, 0.09 ml to 0.11 ml.

[0028] The dose per injection site is preferably 4.5 U to 5.5 U. Thus, the dose per injection site can be, for example, 4.6 U, 4.7 U, 4.8 U, 4.9 U, 5.0 U, 5.1 U, 5.2 U, 5.3 U, and 5.4 U. A particularly preferred dose per injection site is 5.0 U.

[0029] In a preferred embodiment of the first aspect of the invention, the concentration of botulinum toxin is within the range of 40 U / ml to 60 U / ml, for example 45 U / ml, 50 U / ml and 55 U / ml, the dose is 4.0 U to 6.0 U per injection site, and the volume is 0.07 ml to 0.15 ml per injection site. The volume per injection site is preferably 0.07 ml to 0.14 ml, and the most preferred injection volumes are as described above in combination with the first aspect of the invention. The concentration, as used herein, refers to the concentration of botulinum toxin in Petition 870250104861, dated 11 / 17 / 2025, p. 37 / 66 18 / 42 liquid formulation that is administered by subcutaneous injection.

[0030] Preferably, in said preferred embodiment, the dose per injection site is 4.5 U to 5.5 U (including, for example, 4.6 U, 4.7 U, 4.8 U, 4.9 U, 5.0 U, 5.1 U, 5.2 U, 5.3 U, 5.4 U) and, most preferably, 5.0 U) and the volume per injection site is 0.07 ml to 0.14 ml. Preferably, the volume per injection site is 0.08 ml to 0.13 ml, even more preferably, 0.08 ml to 0.12 ml, even more preferably, 0.09 ml to 0.11 ml and, most preferably, 0.10 ml.More specifically, the volume per injection point is preferably 0.07 ml to 0.13 ml, more preferably 0.07 ml to 0.12 ml, even more preferably 0.07 ml to 0.11 ml, or preferably 0.08 ml to 0.14 ml, more preferably 0.08 ml to 0.13 ml, even more preferably 0.08 ml to 0.12 ml, even more preferably 0.08 ml to 0.11 ml, or preferably 0.09 ml to 0.14 ml, more preferably 0.09 ml to 0.13 ml, even more preferably 0.09 ml to 0.12 ml, and even more preferably 0.09 ml to 0.11 ml.

[0031] In accordance with the aspects and embodiments of the present invention, the total dose of botulinum toxin is up to 400 U and / or the total number of injection sites is up to 90. Preferably, the total dose is between 100 U and 400 U. Petition 870250104861, dated 11 / 17 / 2025, pp. 38 / 66 19 / 42 or up to 300 U or between 200 U and 300 U or more than 300 U up to 400 U. Preferably, the total number of injection points is 40 to 90 or 50 to 90 or up to 80 or 50 to 80 or 60 to 80.

[0032] With regard to the injection pattern, the injection points are typically arranged so that the distance between injection points is 1.5 cm to 2.5 cm, preferably 1.6 cm to 2.4 cm, more preferably 1.7 cm to 2.3 cm, even more preferably 1.8 cm to 2.2 cm, even more preferably 1.9 cm to 2.1 cm and, most preferably, 2.0 cm.

[0033] The expression "distance between injection points," as used in this document, means the distance between any given injection point and its nearest injection points. In particular, the expression "distance between injection points" refers to the distance between any given injection point and another injection point that is closest to said given injection point, unless otherwise stated.

[0034] In accordance with the present invention, exemplary preferred combinations of concentration, dose per injection site, volume per injection site and distance between injection sites include the following: (1) concentration of 35 U / ml to 65 U / ml, dose per injection site of 4.0 U to 6.0 U, volume per injection site of 0.08 ml to Petition 870250104861, dated 11 / 17 / 2025, page 39 / 66 20 / 42 0.13 ml, distance between injection points 1.5 cm to 2.5 cm, (2) concentration 35 U / ml to 65 U / ml, dose per injection point 4.0 U to 6.0 U, volume per injection point 0.09 ml to 0.12 ml, distance between injection points 1.5 cm to 2.5 cm, (3) concentration 35 U / ml to 65 U / ml, dose per injection point 4.0 U to 6.0 U, volume per injection point 0.09 ml to 0.11 ml, distance between injection points 1.5 cm to 2.5 cm, (4) concentration 35 U / ml to 65 U / ml, dose per injection point 4.0 U to 6.0 U, volume per injection point 0.07 ml to 0.15 ml, distance between injection points 1.6 cm to 2.4 cm, (5) concentration of 35 U / ml to 65 U / ml, dose per injection site of 4.0 U to 6.0 U, volume per injection site of 0.07 ml to 0.15 ml, distance between injection sites of 1.7 cm to 2.3 cm, (6) concentration of 35 U / ml to 65 U / ml, dose per injection site of 4.0 U to 6.0 U, volume per injection site of 0.07 ml to 0.15 ml, distance between injection sites of 1.8 cm to 2.2 cm,(7) concentration of 35 U / ml to 65 U / ml, dose per injection site of 4.0 U to 6.0 U, volume per injection site of 0.08 ml to 0.13 ml, distance between injection sites of 1.6 cm to 2.4 cm, (8) concentration of 35 U / ml to 65 U / ml, dose per injection site of 4.0 U to 6.0 U, volume per injection site of 0.09 ml to 0.12 ml, distance between injection sites of 1.7 cm to 2.3 cm, (9) concentration of 35 U / ml to 65 U / ml, dose per injection site of 4.0 U to 6.0 U, volume per injection site of, Petition 870250104861, dated 11 / 17 / 2025, pp. 40 / 66 21 / 42 0.09 ml to 0.11 ml, distance between injection points 1.8 cm to 2.2 cm, (10) concentration 35 U / ml to 65 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.07 ml to 0.15 ml, distance between injection points 1.5 cm to 2.5 cm, (11) concentration 35 U / ml to 65 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.08 ml to 0.13 ml, distance between injection points 1.5 cm to 2.5 cm, (12) concentration 35 U / ml to 65 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.08 ml to 0.12 ml, distance between injection points injection from 1.5 cm to 2.5 cm, (13) concentration of 35 U / ml to 65 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.09 ml to 0.11 ml, distance between injection points of 1.5 cm to 2.5 cm, (14) concentration of 40 U / ml to 60 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.07 ml to 0.15 ml, distance between injection points of 1,5 cm to 2.5 cm, (15) concentration of 40 U / ml to 60 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.08 ml to 0.13 ml, distance between injection points of 1.5 cm to 2.5 cm, (16) concentration of 40 U / ml to 60 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.08 ml to 0.12 ml, distance between injection points of 1.5 cm to 2.5 cm, (17) concentration of 40 U / ml to 60 U / ml, dose per injection point of 4.5 U to 5.5 U, volume, Petition 870250104861, dated 11 / 17 / 2025, page 41 / 66 22 / 42 per injection point of 0.09 ml to 0.11 ml, distance between injection points of 1.5 cm to 2.5 cm, (18) concentration of 35 U / ml to 65 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.07 ml to 0.15 ml, distance between injection points of 1.7 cm to 2.3 cm, (19) concentration of 35 U / ml to 65 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.08 ml to 0.13 ml, distance between injection points of 1.7 cm to 2.3 cm, (20) concentration of 35 U / ml to 65 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.08 ml to 0.12 ml, distance between injection points 1.7 cm to 2.3 cm, (21) concentration 35 U / ml to 65 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.09 ml to 0.11 ml, distance between injection points 1.5 cm to 2.5 cm, (22) concentration 35 U / ml to 65 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.07 ml to 0.15 ml,distance between injection points 1.8 cm to 2.2 cm, (23) concentration 35 U / ml to 65 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.08 ml to 0.13 ml, distance between injection points 1.8 cm to 2.2 cm, (24) concentration 35 U / ml to 65 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.08 ml to 0.12 ml, distance between injection points 1.8 cm to 2.2 cm, (25) concentration 35 U / ml to 65 U / ml, dose per injection point 4.5 U to, Petition 870250104861, dated 11 / 17 / 2025, page 42 / 66 23 / 42 5.5 U, volume per injection point 0.09 ml to 0.11 ml, distance between injection points 1.8 cm to 2.2 cm, (26) concentration 40 U / ml to 60 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.07 ml to 0.15 ml, distance between injection points 1.7 cm to 2.3 cm, (27) concentration 40 U / ml to 60 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.08 ml to 0.13 ml, distance between injection points 1.7 cm to 2.3 cm, (28) concentration 40 U / ml to 60 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.08 ml at 0.12 ml, distance between injection points from 1.7 cm to 2.3 cm, (29) concentration from 40 U / ml to 60 U / ml, dose per injection point from 4.5 U to 5.5 U, volume per injection point from 0.09 ml to 0.11 ml, distance between injection points from 1.7 cm to 2.3 cm, (30) concentration from 40 U / ml to 60 U / ml, dose per injection point from 4.5 U to 5.5 U, volume per injection point from 0.07 ml to 0.15 ml,distance between injection points 1.8 cm to 2.2 cm, (31) concentration 40 U / ml to 60 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.08 ml to 0.13 ml, distance between injection points 1.8 cm to 2.2 cm, (32) concentration 40 U / ml to 60 U / ml, dose per injection point 4.5 U to 5.5 U, volume per injection point 0.08 ml to 0.12 ml, distance between injection points 1.8 cm to 2.2 cm, (33) concentration 40 U / ml to 60 U / ml, dose per point, Petition 870250104861, dated 11 / 17 / 2025, page 43 / 66 24 / 42 injection of 4.5 U to 5.5 U, volume per injection point of 0.09 ml to 0.11 ml, distance between injection points of 1.8 cm to 2.2 cm, (34) concentration of 50 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.09 ml to 0.11 ml, distance between injection points of 1.5 cm to 2.5 cm, (35) concentration of 50 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.09 ml to 0.11 ml, distance between injection points of 1.7 cm to 2.3 cm, (36) concentration of 50 U / ml, dose per injection point of 4.5 U to 5.5 U, volume per injection point of 0.09 ml to 0.11 ml, distance between injection points from 1.8 cm to 2.2 cm, (37) concentration from 40 U / ml to 60 U / ml, dose per injection point of 5.0 U, volume per injection point from 0.083 ml to 0.125 ml, distance between injection points from 1.5 cm to 2.5 cm, (38) concentration from 40 U / ml to 60 U / ml, dose per injection point of 5.0 U, volume per injection point from 0.083 ml to 0.125 ml,distance between injection points of 1.7 cm to 2.3 cm, (39) concentration of 40 U / ml to 60 U / ml, dose per injection point of 5.0 U, volume per injection point of 0.083 ml to 0.125 ml, distance between injection points of 1.8 cm to 2.7 cm, (40) concentration of 50 U / ml, dose per injection point of 5.0 U, volume per injection point of 0.10 ml, distance between injection points of 1.5 cm to 2.5 cm, (41) concentration of 50 U / ml, dose per injection point of 5.0 U, volume per injection point of 0.10 ml, Petition 870250104861, dated 11 / 17 / 2025, pp. 44 / 66 25 / 42 distance between injection points of 1.7 cm to 2.3 cm, (42) concentration of 50 U / ml, dose per injection point of 5.0 U, volume per injection point of 0.10 ml, distance between injection points of 1.8 cm to 2.2 cm, (43) concentration of 50 U / ml, dose per injection point of 5.0 U, volume per injection point of 0.10 ml, distance between injection points of 1.9 cm to 2.1 cm, (44) concentration of 50 U / ml, dose per injection point of 5.0 U, volume per injection point of 0.10 ml, distance between injection points of 2.0 cm.

[0035] According to the present invention, the particularly preferred combinations of (1) to (44) can be further combined with a total dose of up to 400 U or 100 U to 400 U or up to 300 U or between 200 U and 300 U or more than 300 U to 400 U. In addition, the particularly preferred combinations of (1) to (44) can be further combined with a total number of injection points of up to 90 or 40 to 90 or 50 to 90 or up to 80 or 50 to 80 or 60 to 80. Furthermore, the particularly preferred combinations of (1) to (44) can be further combined with one or more of the following combinations: (I) a total dose of up to 400 U and a total number of injection points of up to 90, (II) a total dose of 200 U to 400 U and a total number of injection points of up to 90. (III) a total dose of 200 U to 300 U and a total number of injection points of up to 90, (IV) a total dose greater than 300 U to 400 U and a total number of injection points of up to 90 Petition 870250104861, dated 11 / 17 / 2025, pp. 45 / 66 26 / 42 injection points up to 90, (V) a total dose of up to 400 U and a total number of injection points from 40 to 90, (VI) a total dose of 200 U to 400 U and a total number of injection points from 40 to 90, (VII) a total dose of 200 U to 300 U and a total number of injection points from 40 to 90, (VIII) a total dose greater than 300 U to 400 U and a total number of injection points from 40 to 90, (IX) a total dose of up to 400 U and a total number of injection points from 50 to 80, (X) a total dose of 200 U to 400 U and a total number of injection points from 50 to 80, (XI) a total dose of 200 U to 300 U and a total number of injection points from 50 to 80, and (XII) a total dose greater than 300 U to 400 U and a total number of injection sites from 50 to 80.

[0036] The injection points are typically arranged in a grid pattern, preferably in a square grid, more preferably in a rectangular grid in which each of the four injection points forms a rectangle, where one is equally spaced from the other (i.e., there are four equidistant neighboring injection points for each injection point) and, most preferably, in a square grid.

[0037] In the context of the present invention, peripheral neuropathic pain is preferably selected from the group consisting of postherpetic neuralgia, peripheral nerve injury, trigeminal neuralgia, Petition 870250104861, dated 11 / 17 / 2025, pp. 46 / 66 27 / 42 painful polyneuropathy and painful radiculopathy. In a particularly preferred way, peripheral neuropathic pain is post-herpetic neuralgia, peripheral nerve injury or painful polyneuropathy, including diabetic neuropathic pain.

[0038] The botulinum toxin used in the present invention is not particularly limited to this and includes botulinum toxin of any serotype (BoNT / AH) in a form that is free of complexing proteins or in the form of a complex containing complexing proteins. Preferably, the botulinum toxin is of serotype A or B (BoNT / A, BoNT / B), wherein serotype A (BoNTA) is particularly preferred. More preferably, the botulinum toxin is of serotype A, even more preferably of serotype A1 (BoNT / A1), and most preferably BoNT / A1 produced by the Hall strain of Clostridium botulinum. Preferably, the botulinum toxin is of type A and is in a form that is free of complexing proteins, or it is in the form of a complex that contains complexing proteins, and more preferably, it is botulinum toxin of type A in a form that is free of complexing proteins.

[0039] As defined herein, the term botulinum toxin (BT) is used synonymously with the term botulinum neurotoxin (BoNT). These terms are intended to refer to a form of toxin that is free Petition 870250104861, dated 11 / 17 / 2025, pp. 47 / 66 28 / 42 of complexing proteins, that is, the neurotoxic (active) polypeptide that ultimately inhibits the release of acetylcholine (also referred to in this document as pure botulinum neurotoxin, neurotoxic component, 150 kDa neurotoxin or Clostridium botulinum neurotoxin (150 kDa)) and a form of toxin that is a complex containing complexing proteins (i.e., a complex of the neurotoxic component and complexing proteins). The botulinum toxin complex is a high molecular weight complex of the neurotoxic component and a set of complexing proteins (NAPs), including the 900 kDa, 500 kDa and 300 kDa C. botulinum type A toxin complexes. The complexing proteins are non-toxic non-hemagglutinin (NTNHA) and, in serotype AD strains, different hemagglutinins (HAs). For example, the 900 kDa complex is included in OnabotulinumtoxinA (Botox® / Vistabel®, Allergan, Inc.)., Irvine, CA, USA) and also in AbobotulinumtoxinA (Dysport®, Azzalure®, Ipsen, Paris, France); Alluzience® (Ipsen / Galderma) and Innotox® (Medytox) contain a toxin complex as the active agent. Preferably, the botulinum toxin is the pure botulinum neurotoxin contained in Xeomin® or is Xeomin®, or is the toxin complex contained in Botox® or Dysport® or is Botox® or Dysport®.

[0040] In the context of the present invention, botulinum toxin can be a natural neurotoxin obtainable from Petition 870250104861, dated 11 / 17 / 2025, pp. 48 / 66 29 / 42 Clostridium botulinum bacteria or any other botulinum toxin, such as a botulinum toxin obtainable from alternative sources, including recombinant technologies and genetic or chemical modification. Chimeric or genetically modified botulinum toxins, i.e., botulinum toxins containing mutations including substitutions, deletions, and insertions, are also encompassed by the terms botulinum toxin, neurotoxic component, and the like. Preferably, the mutation does not comprise any of the biological activities of the botulinum toxin. However, the use of mutations to modulate the biological activity of the botulinum toxin is also foreseen. Also included are botulinum toxins containing chemically modified amino acids, for example, one or more amino acids that are glycosylated, acetylated, or otherwise, which may be beneficial for the absorption or stability of the toxin. Of particular preference is the lipidation of the neurotoxic component.

[0041] In the context of the present invention, the dose is expressed in biological units, since botulinum toxin may contain, for example, varying percentages of inactive toxin that contribute to the overall protein load without contributing to efficacy. In the context of the present invention, the biological potency of botulinum toxin is determined using mouse biomass (MBA). MBA determines the median lethal dose (LD50) of toxin / neurotoxin after injection. Petition 870250104861, dated 11 / 17 / 2025, pp. 49 / 66 30 / 42 intraperitoneal in mice, that is, the dose of toxin / neurotoxin capable of killing 50% of a group of mice. Based on this, 1 unit (U) of toxin / neurotoxin, as used in this document, is defined as a mouse LD50 (1.0 LD50 = 1.0 U). The mouse LD50 biological assay is the gold standard among various methods of biological, chemical or immunological detection and determination of activity for botulinum toxin, and is known to those skilled in the art (see, for example, Pearce, LB; Borodic, GE; First, ER; MacCallum, RD Measurement of botulinum toxin activity: Evaluation of the lethality assay. Toxicol. Appl. Pharmacol. 1994, 128, 69-77).

[0042] Another useful method for determining the biological activity (biological potency) of a botulinum neurotoxin is a cell-based potency assay as described, for example, in documents no. WO2009 / 114748, WO 2013 / 049508 or WO 2014 / 207109. The activity results obtained with such cell-based assays correspond to the activity values ​​obtained in the mouse LD50 ip assay, as the values ​​are calibrated using the LD50 reference standard.

[0043] Due to differences in the LD50 tests used by manufacturers of commercial botulinum toxin formulations, the unit potencies indicated by the manufacturers for their Petition 870250104861, dated 11 / 17 / 2025, pp. 50 / 66 31 out of 42 commercial botulinum toxin formulations are registered and cannot be easily compared. Therefore, in the framework of the present invention, the conversion rates provided below are used to establish the comparative potencies of IncobotulinumtoxinA (INCO; Xeomin®, Bocouture®; botulinum toxin serotype A, free of complexing proteins; Merz Pharmaceuticals GmbH), OnabotulinumtoxinA (ONA; Botox®, Vistabel®; botulinum toxin complex serotype A; Allergan Inc.), AbobotulinumtoxinA (ABO; Dysport®, Azzalure®; botulinum toxin complex serotype A; Medicis Pharmaceutical Corp., Galderma Lab.), RimabotulinumtoxinB (RIM; Myobloc®, NeuroBloc®; botulinum toxin serotype B; Solstice Neurosciences Inc.) and PurTox® (TBD; botulinum toxin serotype A; Mentor Worldwide LLC). For the purposes of this document, the ONA to INCO conversion ratio is 1:1. The ONA / INCO to ABO conversion ratio is 1:2.5.The conversion ratio of ONA / INCO:RIM is 1:50, and the conversion ratio of ONA / INCO:TBD is 1:1.5. Furthermore, and preferably within the context of the present invention, 1 U of INCO (Xeomin®) and 1 U of OnabotulinumtoxinA (ONA; Botox®) should be considered as corresponding to a mouse LD50 (1.0 LD50), or 1 U, measured as described above.

[0044] In general, the botulinum toxin used within the present invention is in the form of a liquid composition. Petition 870250104861, dated 11 / 17 / 2025, pp. 51 / 66 32 / 42 The liquid composition can be formulated by various techniques depending on the desired application, as known in the art. It can be supplied as a ready-to-use liquid formulation or in the form of a lyophilized powder that must be reconstituted, typically in physiological saline solution, before use. Preferably, the botulinum toxin used within the present invention is in the form of an aqueous solution, more preferably a saline solution or a physiological saline solution, and most preferably a phosphate-buffered physiological saline solution. The aqueous solution may further comprise one or more pharmaceutically acceptable substances. Suitable pharmaceutically acceptable substances comprise substances known in the art; see, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania.

[0045] In particular, the aqueous solution or composition of botulinum toxin may include other non-toxic, non-therapeutic, and non-immunogenic carriers or stabilizers and the like. Thus, the aqueous composition of botulinum toxin may contain glycerol, protein stabilizers (HSAs), or non-protein stabilizers such as polyvinyl pyrrolidone (PVP), hyaluronic acid, or free amino acids, for example, methionine or histidine. Non-proteinaceous stabilizers are described in the documents Petition 870250104861, dated 11 / 17 / 2025, pp. 52 / 66 33 / 42 No. WO 2005 / 007185 or No. WO 2006 / 020208. Furthermore, they may be free of amino acids and / or free of stabilizing peptides (for example, consisting of 5 to 50 amino acids, 10 to 40 amino acids, or 15 to 30 amino acids). The botulinum toxin composition may also include a non-ionic or ionic surfactant, for example, polysorbate or poloxamer. A suitable formulation for an HSA-stabilized formulation comprising a botulinum toxin according to the present invention is described, for example, in document No. US 8,398,998 B2.

[0046] Preferably, the botulinum toxin used in the present invention is in the form of an aqueous solution comprising sodium chloride (NaCl), preferably in the form of a physiological saline solution (i.e., a solution that includes sodium chloride at a physiological concentration, for example, about 9 g / l of NaCl), which further comprises one or more of the following (i) to (ix): (i) no other excipient (except NaCl), (ii) human serum albumin (HSA) and a sugar, in particular, a monosaccharide or a disaccharide, (iii) human serum albumin (HSA) and lactose, (iv) human serum albumin (HSA) and sucrose, (v) a monosaccharide and / or a disaccharide (for example, lactose and / or sucrose), (vi) no buffer, (vii) no amino acid, (viii) no human serum albumin (HSA), sodium chloride and lactose or no HSA, sodium chloride sodium and sucrose or Petition 870250104861, dated 11 / 17 / 2025, pp. 53 / 66 34 / 42 (ix) no HSA and sodium chloride or any combination of (i) to (ix).

[0047] In a particularly preferred embodiment, botulinum toxin is in the form of an aqueous formulation comprising botulinum toxin, sodium chloride and human serum albumin or an aqueous formulation comprising botulinum toxin, sodium chloride, human serum albumin and lactose or an aqueous formulation comprising botulinum toxin, sodium chloride, human serum albumin and sucrose. Another aqueous formulation in a particularly preferred embodiment comprises botulinum toxin, sodium chloride, human serum albumin and histidine. Botulinum toxin may be as defined above in this document.

[0048] In a second aspect, the present invention relates to a method for the treatment of peripheral neuropathic pain, wherein the method comprises administering an effective amount of botulinum toxin by subcutaneous injection into an area of ​​a patient's skin at a concentration of 35 U / ml to 65 U / ml, and at a dose of 4.0 U to 6.0 U per injection point and a volume of 0.07 ml to 0.15 ml per injection point, and wherein the distance between injection points is 1.5 cm to 2.5 cm.

[0049] The method according to the second aspect of the present invention refers precisely to the use according to the first aspect of the present invention. Thus, all the Petition 870250104861, dated 11 / 17 / 2025, pp. 54 / 66 35 / 42 definitions, explanations, advantages, etc. provided in this document with respect to the use according to the first aspect of the present invention, apply equally to the method according to the second aspect of the present invention. Example Efficacy and safety of botulinum toxin in the treatment of peripheral neuropathic pain using the dosage and injection regimen according to the present invention.

[0050] A parallel-group, placebo-controlled, multicenter, double-blind, randomized, two-arm, proof-of-concept clinical study is conducted to investigate the efficacy and safety of subcutaneous injection of botulinum toxin (botulinum neurotoxin or BoNT), in particular, botulinum toxin type A (BoNT / A), for example, NT 201 (Xeomin®), in the treatment of peripheral neuropathic pain. The medical condition studied is moderate to severe chronic PNP due to postherpetic neuralgia (PHN) or peripheral nerve injury (postsurgical / posttraumatic neuropathic pain).

[0051] The study includes a total of, for example, 120 individuals aged 18 years or older (male or female). The main inclusion criteria include (1) chronic PNP that persists for at least 6 months at the time of the screening visit and is plausibly Petition 870250104861, dated 11 / 17 / 2025, pages 55 / 66 36 / 42 related to either an episode of herpes zoster or a peripheral nerve injury (caused by surgery or mechanical trauma), (2) documented diagnosis of chronic neuropathic pain following peripheral nerve injury (i.e., post-surgical / post-traumatic neuropathic pain) or PHN with at least a probable level of uncertainty according to the NeuPSIG / IASP classification system, and (3) a score of at least 4 out of 10 points on the 4-Question Neuropathic Pain Questionnaire (DN4).

[0052] Individuals are randomized with a 1:1 ratio, which establishes approximately 60 individuals in the BoNT group and 60 individuals in the placebo group. At baseline (Day 1), individuals receive a single intervention session with subcutaneous injections of BoNT or placebo into the area of ​​skin with PNP. The BoNT formulation used has a concentration of 50 U / ml and can be prepared by reconstituting, for example, a 100 U vial of botulinum toxin, e.g., NT 201 (Xeomin®), with 2 ml of sterile physiological saline sodium chloride solution (0.9%), resulting in a concentration of 50 U / ml. The total injected dose of BoNT can be up to 400 U and, in this example, is up to 300 U, divided into up to 60 subcutaneous (SC) injections (i.e., 5 U per site). The injections are arranged in a square grid pattern with a distance of 2 cm between injection points. Individuals in the placebo group receive a placebo solution (0.9% chloride of Petition 870250104861, dated 11 / 17 / 2025, pages 56 / 66 37 / 42 sodium) containing only the excipients of the saline solution used for botulinum toxin (i.e., sucrose and human serum albumin in the case of NT 201).

[0053] Next, all randomized individuals are followed during a double-blind follow-up period of, for example, 20 weeks with daily self-administration clinical outcome assessments (injection session on Day 1). Efficacy variables are determined in the last 7 days prior to baseline (Day 1) and daily or at regular intervals until the end of the study to assess the change in intensity at the end of the study in order to evaluate the change in PNP intensity. The last seven days prior to Day 1 serve as a 7-day baseline pain assessment period. In addition, safety is assessed as known by a person skilled in the art, using safety parameters including Adverse Events (AEs), AEs of Special Interest (AEIs), and Serious Adverse Events (SAEs).At the EoS visit after 20 weeks, a global assessment of overall treatment tolerability on a 4-point response scale (1 = very good, 2 = good, 3 = moderate, 4 = poor) is performed by the investigator.

[0054] The primary variable efficacy is average daily pain (ADP) in weeks 2 to Petition 870250104861, dated 11 / 17 / 2025, pp. 57 / 66 38 / 42 12, established by daily self-assessments by individuals. This variable provides evidence of the effectiveness of BoNT in treating PNP compared to placebo. Pain resulting from chronic neuropathy is the primary symptom that directly impacts the patient's quality of life. The secondary efficacy variable is the change from baseline in the total Neuropathic Pain Symptom Inventory (NPSI) score in weeks 2 to 12, regularly self-assessed (e.g., every 7 days) by individuals. This variable is used to estimate the reduction in the severity of PNP symptoms in PNP treatment compared to placebo. The assessments of these primary and secondary efficacy variables, as well as other efficacy variables, are further explained below.

[0055] NRS for ADP, WDP, and LDP. Participants will record the intensity of their ADP (average daily pain) as well as their WDP (worst daily pain) and LDP (least daily pain) over the past 24 hours on the Neuropathic Pain Numerical Rating Scale (NRS). Each rating will be scored on an 11-point NRS on a range from “0 - ​​No Pain” to “10 - The worst pain imaginable”. NRS ratings of ADP intensity Petition 870250104861, dated 11 / 17 / 2025, pp. 58 / 66 39 / 42 are often used as primary efficacy in clinical pain trials and are recommended by authorities in the guidance documents “Guideline on the clinical development of medicinal products intended for the treatment of pain” (2016) by the European Medicines Agency (EMA) and “Guidance for Industry Analgesic Indications: Developing Drug and Biological Products (Draft Guidance)” (2014) by the US Food and Drug Administration (FDA).

[0056] NPSI. Participants will regularly complete the Neuropathic Pain Symptom Inventory (NPSI), a 12-item questionnaire for assessing typical neuropathic pain symptoms (Bouhassira et al., Pain, 2004, 108(3):248-57). The NPSI contains ten items in the form of questions to the participant about the average severity of typical neuropathic pain symptoms, such as spontaneous pain (items 1-3), pain attacks (items 5-6), provoked pain (items 8-10) or abnormal sensations (items 11-12) during the last 24 hours. The items are rated on an 11-point scale ranging from 0, which indicates no symptoms (e.g., "No pain" or "No tingling"), to 10, which indicates the highest imaginable intensity of symptoms (e.g., "Worst imaginable pain" or "Worst imaginable tingling"). The 10 items are used to calculate a total NPSI score, as well as five... Petition 870250104861, dated 11 / 17 / 2025, pp. 59 / 66 40 / 42 subscores for different pain domains: burning pain (spontaneous superficial), pressure pain (spontaneous deep), paroxysmal pain, evoked pain, paresthesia / dysesthesia. These classifications should also be used for sensory phenotyping. In addition, the NPSI contains two items on the duration of spontaneous pain per day (item 4) and the frequency of pain attacks per day (item 7), with five response options each.

[0057] PGIC. In the Patient Global Impression of Change (PGIC) assessment, participants are asked to indicate their perception of change since the study treatment, using a 9-point Likert scale (from “4 - much worse” to “+4 - much better”).

[0058] EQ-5D-5L and EQ VAS. The EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire documents the health status of participants on the day of assessment for the five dimensions of mobility, self-care, normal activities, pain / discomfort, and anxiety / depression (Herdman M, Gudex C, Lloyd A, et al., Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual. Life Res.). For each dimension, participants can choose from five response options indicating no problems, some problems, moderate problems, problems Petition 870250104861, dated 11 / 17 / 2025, pp. 60 / 66 41 / 42 serious or extreme problems in each domain. Participants also rate their overall health on the day of the assessment on the EuroQol Visual Analogue Scale 0 to 100 (EQVAS), which ranges from “0 - ​​The worst state of health imaginable” to “100 - The best state of health imaginable”.

[0059] BPI-SF Interference. For the seven interference items of the Brief Pain Inventory - Short Form Interference (BPI-SF Interference), participants report how pain interfered with their overall activity, mood, ability to walk, normal work, relationships with others, sleep, and enjoyment of life during the past 24 hours (Cleeland, CS and Ryan, KM, Ann. Acad. Med. Singap., 1994, 23(2):129-38). The items are rated on an 11-point scale ranging from 0 indicating no interference (“Does not interfere”) to 10 indicating complete interference (“Completely interferes”).

[0060] HADS. The Hospital Anxiety & Depression Scale (HADS) will be used to quantify anxiety and depression. Each of the two domains is covered by seven items with four response options (Zigmond AS and Snaith RP, Acta Psychiatr. Scand., 1983, 67(6):361-70). The response options refer precisely to the concept of anxiety or Petition 870250104861, dated 11 / 17 / 2025, pages 61 / 66 42 / 42 depression, and related questions refer, for example, to how often or how much the patient feels this way.

[0061] The approach described above, which involves a combination of injection dose, injection volume, number of injections and distance between injection points, provides a local and minimally invasive alternative to established PNP therapies that is effective, well tolerated and safe. Petition 870250104861, dated 11 / 17 / 2025, pages 62 / 66

Claims

1 / 3 CLAIMS 1. Use of a botulinum toxin characterized by the fact that the use is for the manufacture of a medicament for the treatment of peripheral neuropathic pain, wherein the botulinum toxin is injected subcutaneously into an area of ​​a patient's skin at a concentration of 35 U / ml to 65 U / ml, and at a dose of 4.0 U to 6.0 U per injection point and at a volume of 0.07 ml to 0.15 ml per injection point; and wherein the distance between injection points is 1.5 cm to 2.5 cm.

2. Use according to claim 1, characterized in that the volume per injection point is 0.08 ml to 0.13 ml.

3. Use according to claim 1 or 2, characterized in that the dose per injection site is 4.5 U to 5.5 U.

4. Use according to claim 1 or 2, characterized in that the concentration is 40 U / ml to 60 U / ml.

5. Use according to claim 4, characterized in that the dose per injection site is 4.5 U to 5.5 U and the volume per injection site is 0.07 ml to 0.14 ml.

6. Use according to claim 5, characterized in that the volume per injection point is 0.08 ml to 0.13 ml. Petition 870260032284, dated 07 / 04 / 2026, page 9 / 15 2 / 3 7. Use, according to any one of claims 1 to 6, characterized in that the distance between injection points is 1.8 cm to 2.2 cm.

8. Use, according to any one of claims 1 to 7, characterized in that the total dose is up to 400 U or the total number of injection sites is up to 90, or in that the total dose is up to 400 U and the total number of injection sites is up to 90.

9. Use according to claim 8, characterized in that the total dose is between 100 U and 400 U, or up to 300 U, or between 200 U and 300 U, or from more than 300 U to 400 U, or the total number of injection points is 40 to 90 or 50 to 90 or up to 80 or 50 to 80 or 60 to 80, or in which the total dose is between 100 U and 400 U or up to 300 U or between 200 U and 300 U or from more than 300 U to 400 U and the total number of injection points is 40 to 90 or 50 to 90 or up to 80 or 50 to 80 or 60 to 80.

10. Use, according to any one of claims 1 to 9, characterized in that the injection points are arranged in a grid pattern that includes a quadrangular grid, a rectangular grid in which each of the four injection points forms a rectangle and are equally spaced from each other, and a square grid.

11. Use, according to any of claims 1 to 10, characterized in that peripheral neuropathic pain is selected from the group consisting of postherpetic neuralgia, peripheral nerve injury, trigeminal neuralgia, painful polyneuropathy and painful radiculopathy.

12. Use, according to claim 11, characterized in that the peripheral neuropathic pain is post-herpetic neuralgia, peripheral nerve injury or painful polyneuropathy including diabetic neuropathic pain.

13. Use, according to any one of claims 1 to 12, characterized in that the botulinum toxin is of type A.

14. Use, according to any one of claims 1 to 13, characterized in that the botulinum toxin is in a form that is free of complexing proteins or is in the form of a complex that contains complexing proteins.

15. Composition for the treatment of peripheral neuropathic pain, characterized in that it comprises botulinum toxin at a concentration of 35 U / ml to 65 U / ml and a pharmaceutically acceptable excipient, wherein the composition comprises 4.0 U to 6.0 U of botulinum toxin per dose for subcutaneous injection, and a volume of 0.07 ml to 0.15 ml per subcutaneous injection. Petition 870260032284, dated 07 / 04 / 2026, page 11 / 15